Tarsier Pharma
Clinical-stage company developing novel treatments for ocular inflammatory blinding diseases.
About
Tarsier Pharma is a late clinical-stage company developing bio-inspired medical solutions for autoimmune and inflammatory ocular diseases. Their breakthrough platform technology, Dazdotuftide (TRS), aims to re-engineer the immune system to treat conditions like uveitis, with a pipeline including eye drops and intravitreal injections. They serve patients suffering from blinding ocular diseases and provide information for healthcare providers and investors. Teams look it up for Healthcare, Disease Treatment, Vision Impairment.
Frequently asked
What does Tarsier Pharma do?
Tarsier Pharma is a Healthcare company that offers Services. Teams look it up for Disease Treatment, Vision Impairment, Biotech. It is based in Tel Aviv, Israel and was founded in 2016. Public records show about 12 people and $5M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Tarsier Pharma raised?
Tarsier Pharma has raised a total of $5M in funding. The most recent round on record is Series B.
Where is Tarsier Pharma headquartered?
Tarsier Pharma is headquartered in Tel Aviv, Israel.
When was Tarsier Pharma founded?
Tarsier Pharma was founded in 2016.
What industry does Tarsier Pharma operate in?
Tarsier Pharma operates in Healthcare, Disease Treatment, Vision Impairment, Biotech, MedTech.
How many employees does Tarsier Pharma have?
Tarsier Pharma has approximately 12 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.